Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Caio Max Saeo Pedro Rocha Lima, MD
Open to Accrual
To determine the efficacy, based on PFS, of mFOLFOX6/bevacizumab plus atezolizumab (combination) and atezolizumab (single agent) as compared to mFOLFOX6/bevacizumab (control).
Protocol and Other Documents
Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website
Site Initiation Visit (SIV) Video is posted to CTSU.
NRG-GI004/SWOG-S1610 Request for Supplies from Baylor Serum Bank
/Patients with a diagnosis of metastatic adenocarcinoma of colon or rectum without previous chemotherapy or any other systemic therapy for metastatic colorectal cancer.
Tumor determined to be mismatch-repair deficient (dMMR) by CLIA-certified immunohistochemical (IHC) assay with a panel of all four IHC markers, including MLH1, MSH2, PMS2, and MSH6.
An adequate amount of archived tumor tissue (FFPE), either from primary colorectal cancer site or metastatic lesions, for central confirmation of dMMR status.
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.